Breaking News, Financial News

Financial Reports: Alexion

Soliris continues to rise

Alexion 1Q13

1Q Revenues: $339 million (+38%)

1Q Earnings: $82 million (+81%)

Comments: Sales of Soliris climbed 38% to $339 million, adding patients for both paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) indications. R&D expenses climbed 64% to $75 million as the company advanced five clinical programs, including one with Soliris.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters